Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M.

Eur Respir J. 2018 Aug 30;52(2). pii: 1701857. doi: 10.1183/13993003.01857-2017. Print 2018 Aug.

PMID:
29976656
2.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

3.

Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage.

Hambly N, Cox G, Kolb M.

Eur Respir J. 2017 May 19;49(5). pii: 1700811. doi: 10.1183/13993003.00811-2017. Print 2017 May. No abstract available.

4.

Pathways to Precision Medicine in Idiopathic Pulmonary Fibrosis. Time to Relax?

Hambly N, Kolb M.

Am J Respir Crit Care Med. 2016 Dec 1;194(11):1315-1317. No abstract available.

PMID:
27905849
5.

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry.

Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M.

Can Respir J. 2016;2016:3562923. doi: 10.1155/2016/3562923. Epub 2016 Apr 5.

6.

High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study.

Ryerson CJ, Camp PG, Eves ND, Schaeffer M, Syed N, Dhillon S, Jensen D, Maltais F, O'Donnell DE, Raghavan N, Roman M, Stickland MK, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, Johannson KA, Kalluri M, Khalil N, Kolb M, Manganas H, Morán-Mendoza O, Provencher S, Ramesh W, Rolf JD, Wilcox PG, Guenette JA.

Ann Am Thorac Soc. 2016 Sep;13(9):1640-7. doi: 10.1513/AnnalsATS.201604-267OC.

PMID:
27348402
7.

Pulmonary hypertension: diagnostic approach and optimal management.

Hambly N, Alawfi F, Mehta S.

CMAJ. 2016 Aug 9;188(11):804-12. doi: 10.1503/cmaj.151075. Epub 2016 May 2. Review. No abstract available.

8.

Riociguat for the treatment of pulmonary hypertension.

Hambly N, Granton J.

Expert Rev Respir Med. 2015;9(6):679-95. doi: 10.1586/17476348.2015.1106316. Epub 2015 Nov 24. Review.

PMID:
26599488
9.

The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry.

Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, Johannson KA, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M.

Can Respir J. 2015 Nov 2. pii: 17206. [Epub ahead of print] No abstract available.

PMID:
26523546
10.

Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers.

Hambly N, Shimbori C, Kolb M.

Respirology. 2015 Oct;20(7):1010-22. doi: 10.1111/resp.12569. Epub 2015 Jun 24. Review.

11.
12.

Monoclonal antibodies for the treatment of refractory asthma.

Hambly N, Nair P.

Curr Opin Pulm Med. 2014 Jan;20(1):87-94. doi: 10.1097/MCP.0000000000000007. Review.

PMID:
24275927
13.

A luminous quasar at a redshift of z = 7.085.

Mortlock DJ, Warren SJ, Venemans BP, Patel M, Hewett PC, McMahon RG, Simpson C, Theuns T, Gonzáles-Solares EA, Adamson A, Dye S, Hambly NC, Hirst P, Irwin MJ, Kuiper E, Lawrence A, Röttgering HJ.

Nature. 2011 Jun 29;474(7353):616-9. doi: 10.1038/nature10159.

14.

Implementation of evidence-based guidelines for thyroid nodule biopsy: a model for establishment of practice standards.

Hambly NM, Gonen M, Gerst SR, Li D, Jia X, Mironov S, Sarasohn D, Fleming SE, Hann LE.

AJR Am J Roentgenol. 2011 Mar;196(3):655-60. doi: 10.2214/AJR.10.4577.

PMID:
21343510
15.

Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up.

Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA.

AJR Am J Roentgenol. 2011 Jan;196(1):218-24. doi: 10.2214/AJR.10.4550.

PMID:
21178070
16.

Comparison of digital mammography and screen-film mammography in breast cancer screening: a review in the Irish breast screening program.

Hambly NM, McNicholas MM, Phelan N, Hargaden GC, O'Doherty A, Flanagan FL.

AJR Am J Roentgenol. 2009 Oct;193(4):1010-8. doi: 10.2214/AJR.08.2157.

PMID:
19770323
17.

Case report. Glioblastoma multiforme presenting as a haemorrhagic minimally enhancing mass of the trigone.

Hambly NM, Farrell MA, Scanlon TG, McErlean A, Kavanagh EC.

Br J Radiol. 2009 Oct;82(982):e204-7. doi: 10.1259/bjr/41022799.

PMID:
19759207
18.
19.

Restenosis following percutaneous renal artery revascularization.

Kane GC, Hambly N, Textor SC, Stanson AW, Garovic VD.

Nephron Clin Pract. 2007;107(2):c63-9. Epub 2007 Sep 11.

PMID:
17848809
20.

Direct detection of galactic halo dark matter.

Oppenheimer BR, Hambly NC, Digby AP, Hodgkin ST, Saumon D.

Science. 2001 Apr 27;292(5517):698-702. Epub 2001 Mar 22.

21.

Infrared spectrum of an extremely cool white-dwarf star

Hodgkin ST, Oppenheimer BR, Hambly NC, Jameson RF, Smartt SJ, Steele IA.

Nature. 2000 Jan 6;403(6765):57-9.

PMID:
10638748

Supplemental Content

Loading ...
Support Center